INSIGHTS ON DRUG DEVELOPMENT

• Simplify And Streamline Method Development With In Silico Modeling

  Automated screening paired with in silico modeling can cut method development time while improving robustness. See how combining experimentation and simulation enables faster decision‑making.

• Building A Science- And Risk-Based Bio-Decontamination Strategy

  Annex 1 has made bio-decontamination central to sterility assurance, with isolator and barrier cycles now expected to be designed, justified, and reviewed across their lifecycle.

• Rapid Automated Selection Of Mammalian Cell Colonies

  Discover how a new technology cultivates mammalian cells into clonal colonies and images them using fluorescent assays to isolate clonal cell populations based on surface protein expression.

• Particles In High Concentration Biotherapeutics

  Examine advanced analytical solutions that detect, characterize, and mitigate particle formation in high-concentration biotherapeutics caused by protein aggregation and surfactant degradation.

• Ask Us Anything: Miles Blackburn On Advances In Flow And Radical Chemistry

  7/23/2026

  Miles Blackburn, Associate Director of Chemistry at Snapdragon Chemistry, on why the biggest payoff of flow and radical chemistry is speed — processes that scale fast enough to get intermediates and APIs delivered on a clinical timeline.

• Navigating Emerging Therapeutics: Cannabinoid And Psilocybin Drug Development

  1/15/2026

  Cannabinoid and psilocybin therapies are advancing rapidly, and Mikart supports innovators with DEA-licensed facilities, formulation expertise, regulatory guidance, and manufacturing capabilities from clinical development to commercialization.

• The Simplest, Most Powerful Digital PCR Workflow Family

  3/26/2026

  Scalable digital PCR provides high-throughput automation for up to 384 samples. Support seven-color multiplexing and 3D data analysis to achieve superior sensitivity and streamlined laboratory workflows.

• Fast And Efficient Processing Of ELISA Assays

  10/24/2025

  Explore how a streamlined ELISA workflow using automated washing and reading tools enabled accurate detection of hepatitis B markers with no false results.

• The Patent Cliff Looms – Design Your Biosimilar Approach Accordingly

  3/3/2025

  In your pursuit of developing a high-quality biosimilar, think strategically. Consider what type of biologic your team’s expertise can support and which is needed most in your target market.